ProShare Advisors
RLAY icon

ProShare Advisors’s Relay Therapeutics RLAY Stock Holding History

ProShare Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$528K Sell
28,197
-212
-0.7% -$3.08K ﹤0.01% 1058
2026
Q1 		$283K Sell
28,409
-4,982
-15% -$44.6K ﹤0.01% 1373
2025
Q4 		$282K Buy
33,391
+4,615
+16% +$32.9K ﹤0.01% 1494
2025
Q3 		$150K Sell
28,776
-4,781
-14% -$18.2K ﹤0.01% 1768
2025
Q2 		$116K Sell
33,557
-1,325
-4% -$3.94K ﹤0.01% 1851
2025
Q1 		$91.4K Sell
34,882
-7,318
-17% -$28.7K ﹤0.01% 1852
2024
Q4 		$174K Buy
42,200
+15,492
+58% +$84.3K ﹤0.01% 1927
2024
Q3 		$189K Buy
26,708
+5,825
+28% +$43.5K ﹤0.01% 1744
2024
Q2 		$136K Sell
20,883
-5,331
-20% -$36.4K ﹤0.01% 1611
2024
Q1 		$218K Buy
26,214
+3,394
+15% +$33.1K ﹤0.01% 1626
2023
Q4 		$251K Buy
22,820
+3,107
+16% +$26.2K ﹤0.01% 1504
2023
Q3 		$166K Buy
19,713
+102
+0.5% +$1.1K ﹤0.01% 1524
2023
Q2 		$246K Buy
19,611
+1,178
+6% +$14.7K ﹤0.01% 1411
2023
Q1 		$304K Sell
18,433
-2,517
-12% -$45.1K ﹤0.01% 1207
2022
Q4 		$313K Buy
20,950
+3,355
+19% +$64.2K ﹤0.01% 1215
2022
Q3 		$394K Buy
17,595
+538
+3% +$11.8K ﹤0.01% 998
2022
Q2 		$286K Sell
17,057
-7,270
-30% -$156K ﹤0.01% 1239
2022
Q1 		$728K Sell
24,327
-6,173
-20% -$150K ﹤0.01% 1064
2021
Q4 		$936K Buy
30,500
+3,005
+11% +$95K ﹤0.01% 1058
2021
Q3 		$867K Sell
27,495
-4,291
-13% -$144K ﹤0.01% 952
2021
Q2 		$1.16M Buy
31,786
+7,080
+29% +$233K ﹤0.01% 945
2021
Q1 		$854K Buy
24,706
+3,692
+18% +$160K ﹤0.01% 1088
2020
Q4 		$873K Buy
+21,014
New +$950K ﹤0.01% 948

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

ProShare Advisors's RLAY Position: Q2 2026 in Review

ProShare Advisors reduced its Relay Therapeutics (RLAY) stake by 0.75% in Q2 2026, selling an estimated $3.08K and leaving 28,197 shares worth $528K. The position accounts for ﹤0.01% of the portfolio, ranked #1058.

ProShare Advisors first reported a position in RLAY in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.16M in Q2 2021. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • ProShare Advisors held 28,197 shares of Relay Therapeutics worth $528K as of Q2 2026.
  • ProShare Advisors sold 212 Relay Therapeutics shares in Q2 2026, an estimated $3.08K.
  • Relay Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1058 holding.
  • ProShare Advisors first reported a position in Relay Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • ProShare Advisors's Relay Therapeutics position peaked at $1.16M in Q2 2021.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.